Skip to main content
letter
. 2005 Aug;15(8):1073–1078. doi: 10.1101/gr.3688905

Table 1.

Fifteen gene-breaking candidates studied in detail

Accession number Gene name L1 EST % id to L1rp TSD lenb
NM_000245a MET CB988551 97% 13
NM_000740 CHRM3: cholinergic receptor, muscarinic 3 CD654050 98% 6
NM_002499 Neogenin 1 BX951091 96% 8
NM_004411a Dynein AA220950 96% 6
NM_004866a SCAMP1 BE566710 96% 5
NM_005816a CD96 antigen BE568884 98% 13
NM_014497 NP220 nuclear protein BG542212 98% 7
NM_014960 Arylsulfatase G BG994996 96% 8
NM_017679 Breast carcinoma amplified sequence 3 (BCAS3) AJ518836 97% 15
NM_022743 SMYD3 BM809976 97% 8
NM_024583a Secernin 3 AA226814 97% 6
NM_145259 Activin A receptor BE787024 98% 9
NM_175624 RAB3A interacting protein (rabin3) BE617461 99% 11
NM_182758 BX957167 96% 10
NM_198499 CN272126 97% 6

The chimp orthologs of NM_000740, NM_175624, and NM_145259 do not contain an L1 corresponding to the human intronic antisense L1 sequences examined here. TSD, target site duplication.

a

Indicates examples already found by Nigumann et al. (2002).

b

len = length